DaVita HealthCare Partner (DVA)
137.64
+0.00 (0.00%)
NYSE · Last Trade: Feb 10th, 6:11 AM EST
Detailed Quote
| Previous Close | 137.64 |
|---|---|
| Open | - |
| Bid | 135.76 |
| Ask | 141.50 |
| Day's Range | N/A - N/A |
| 52 Week Range | 101.00 - 178.38 |
| Volume | 0 |
| Market Cap | 9.72B |
| PE Ratio (TTM) | 14.20 |
| EPS (TTM) | 9.7 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 1,487,263 |
Chart
About DaVita HealthCare Partner (DVA)
DaVita HealthCare Partners is a leading provider of kidney care services in the United States, offering a comprehensive range of dialysis and related healthcare services for patients with chronic kidney failure and end-stage renal disease. The company operates a vast network of outpatient dialysis centers and provides integrated care management and support for patients through various healthcare services, including nutritional counseling, social services, and patient education. DaVita is committed to improving patient outcomes and enhancing the quality of life for those affected by kidney disease while working closely with healthcare providers, payers, and communities to address the evolving challenges of kidney care. Read More
News & Press Releases
DaVita’s fourth quarter results drew a positive market response, as the company outpaced Wall Street expectations on both revenue and non-GAAP profit. Management identified revenue per treatment growth and disciplined execution in its Integrated Kidney Care (IKC) segment as the main contributors to performance, despite a year-over-year decline in operating margin. CEO Javier Rodriguez highlighted the company’s progress in patient outcomes within IKC programs, citing better treatment adherence and reduced hospitalizations. The quarter also saw the impact of higher health benefit costs, which partially offset operational gains.
Via StockStory · February 9, 2026
Two top Berkshire Hathaway holdings have strong comeback potential, but another one should be avoided for now.
Via The Motley Fool · February 8, 2026
What's going on in today's session: S&P500 moverschartmill.com
Via Chartmill · February 6, 2026
DaVita (DVA) Q2 2025 Earnings Call Transcriptfool.com
Via The Motley Fool · February 4, 2026
DaVita (DVA) Q3 2024 Earnings Call Transcriptfool.com
Via The Motley Fool · February 4, 2026
DaVita Inc (NYSE:DVA) Stock Surges 15% After Q4 2025 Earnings Beatchartmill.com
Via Chartmill · February 2, 2026
Discover which S&P500 stocks are making waves on Friday.chartmill.com
Via Chartmill · February 6, 2026
Investors are still waiting to see how Abel will manage the huge stock portfolio at Berkshire.
Via The Motley Fool · February 6, 2026
Buffett's portfolio moves are a clear reflection of what he thinks about the stock market right now.
Via The Motley Fool · February 5, 2026
Explore the top gainers and losers within the S&P500 index in today's session.chartmill.com
Via Chartmill · February 4, 2026
Which S&P500 stocks have an unusual volume on Wednesday?chartmill.com
Via Chartmill · February 4, 2026
Wednesday's session: top gainers and losers in the S&P500 indexchartmill.com
Via Chartmill · February 4, 2026
DaVita (DVA) Q1 2025 Earnings Call Transcript
Via The Motley Fool · February 4, 2026
Which S&P500 stocks are moving on Tuesday?chartmill.com
Via Chartmill · February 3, 2026
Top movers analysis one hour before the close of the markets on 2026-02-03: top gainers and losers in today's session.chartmill.com
Via Chartmill · February 3, 2026
The market now seems to realize it may have misjudged this company's future.
Via The Motley Fool · February 3, 2026
Shares of dialysis provider DaVita Inc. (NYSE:DVA)
jumped 25.3% in the morning session after the company reported fourth-quarter results that topped Wall Street's expectations and issued a robust earnings forecast for 2026.
Via StockStory · February 3, 2026
Uncover the latest developments among S&P500 stocks in today's session.chartmill.com
Via Chartmill · February 3, 2026
What's going on in today's sessionchartmill.com
Via Chartmill · February 3, 2026
These S&P500 stocks are gapping in today's sessionchartmill.com
Via Chartmill · February 3, 2026
Tuesday's session: gap up and gap down stockschartmill.com
Via Chartmill · February 3, 2026
DaVita (DVA) Q4 2025 Earnings Call Transcript
Via The Motley Fool · February 3, 2026
Dialysis provider DaVita Inc. (NYSE:DVA) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 9.9% year on year to $3.62 billion. Its non-GAAP profit of $3.40 per share was 6.5% above analysts’ consensus estimates.
Via StockStory · February 3, 2026
These S&P500 stocks are moving in today's pre-market sessionchartmill.com
Via Chartmill · February 3, 2026
DaVita said its integrated kidney care unit hit full-year profitability in 2025, a year ahead of its original 2026 target.
Via Stocktwits · February 2, 2026